Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-20T04:32:07.473Z Has data issue: false hasContentIssue false

Chapter 12 - Autoimmune Causes of Medication-Resistant Epilepsy

Published online by Cambridge University Press:  20 August 2020

By
Anteneh M. Feyissa  and
Jeffrey W. Britton
Edited by
John M. Stern ,
Raman Sankar  and
Michael Sperling
John M. Stern
Affiliation:
Geffen School of Medicine at UCLA, Los Angeles, CA
Raman Sankar
Affiliation:
Geffen School of Medicine at UCLA, Los Angeles, CA
Michael Sperling
Affiliation:
Jefferson Hospital for Neurosciences, Philadelphia, PA
Get access

Summary

Epilepsy affects approximately 65 million people worldwide. Despite expanding treatment options, up to one-third of patients remain medically intractable[1]. With the exception of surgery in a subset of these patients, epilepsy treatment is usually limited to suppression of seizures with anti-seizure medications (ASMs). Accumulating data support an autoimmune aetiology in some patients [2,3]. Identification of neural antibodies allows a direct means of establishing an autoimmune cause in many of these cases[3–6]. Table 12.1 shows the best-known currently identified autoimmune epilepsy syndromes.

Type
Chapter
Information
Medication-Resistant Epilepsy
Diagnosis and Treatment
 , pp. 100 - 117
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kwan, P, Brodie, MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314–319Google Scholar
Greco, A, Rizzo, MI, De Virgilio, A, et al. Autoimmun Rev 2016;15:221–225Google Scholar
Irani, SR, Bien, CG, Lang, B. Autoimmune epilepsies. Curr Opin Neurol 2011;24:146–153CrossRefGoogle ScholarPubMed
Suleiman, J, Dale, RC. The recognition and treatment of autoimmune epilepsy in children. Dev Med Child Neurol 2015;57: 431–440CrossRefGoogle ScholarPubMed
Graus, F, Titulaer, MJ, Balu, R, et al. Clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15:391–404Google Scholar
Brenner, T, Sills, GJ, Hart, Y, et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia 2013;54:1028–1035Google Scholar
De Vries, EE, van den Munckhof, B, Braun, KP, et al. Inflammatory mediators in human epilepsy: a systematic review and meta-analysis. Neurosci Biobehav Rev 2016;63:177–190Google Scholar
Johnson, MR, Behmoaras, J, Bottolo, L, et al. Systems genetics identifies Sestrin 3 as a regulator of a proconvulsant gene network in human epileptic hippocampus. Nat Commun 2015;6:6031Google Scholar
Bien, CG, Vincent, A, Barnett, MH, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012;135:1622–1638CrossRefGoogle ScholarPubMed
Byun, JI, Lee, ST, Jung, KH, et al. Effect of immunotherapy on seizure outcome in patients with autoimmune encephalitis: a prospective observational registry study. PLoS One 2016;11:e0146455Google Scholar
Bello-Espinosa, LE, Rajapakse, T, Rho, JM, Buchhalter, J. Efficacy of intravenous immunoglobulin in a cohort of children with drug-resistant epilepsy. Pediatr Neurol 2015;52:509–516Google Scholar
Toledano, M, Britton, JW, McKeon, A, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology 2014;82:1578–1586Google Scholar
Quek, AM, Britton, JW, McKeon, A, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 2012;69:582–593Google Scholar
Ong, M, Kohane, IS, Cai, T, et al. Population-level evidence for an autoimmune etiology of epilepsy. J Am Med Assoc Neurol 2014;71:569–574Google Scholar
Devinsky, O, Schein, A, Najjar, S. Epilepsy associated with systemic autoimmune disorders. Epilepsy Curr 2013;13:62–68Google Scholar
Flanagan, EP, Kotsenas, AL, Britton, JW, et al. Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurol Neuroimmunol Neuroinflamm 2015;2:e161CrossRefGoogle ScholarPubMed
Lai, M, Huijbers, MGM, Lancaster, E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010;9:776–785Google Scholar
Irani, SR, Michell, AW, Lang, B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011;69:892–900Google Scholar
Irani, SR, Gelfand, JM, Bettcher, BM, et al. Effect of rituximab in patients with leucine rich, glioma-inactivated antibody-associated encephalopathy. J Am Med Assoc Neurol 2014;71:896–900Google ScholarPubMed
Krogias, C, Hoepner, R, Müller, A, et al. Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab. J Am Med Assoc Neurol 2013;70:1056–1059Google Scholar
Peery, HE, Day, GS, Dunn, S, et al. Anti-NMDA receptor encephalitis: the disorder, the diagnosis and the immunobiology. Autoimmun Rev 2012;11:863–872Google Scholar
Titulaer, MJ, McCracken, L, Gabilondo, I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157–165Google Scholar
Prud’homme, GJ, Glinka, Y, Wang, Q. Immunological GABAergic interactions and therapeutic applications in autoimmune diseases. Autoimmun Rev 2015;14:1048–1056Google Scholar
Petit-Pedrol, M, Armangue, T, Peng, X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterization of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014;13:276–286Google Scholar
Lancaster, E, Lai, M, Peng, X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures case series and characterization of the antigen. Lancet Neurol 2010;9:67–76Google Scholar
Lai, M, Hughes, EG, Peng, X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009;65:424–434Google Scholar
Carvajal-González, A, Leite, MI, Waters, P, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain 2014;137:2178–2192Google Scholar
Lancaster, E, Martinez-Hernandez, E, Titulaer, MJ, et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 2011;77:1698–1701CrossRefGoogle ScholarPubMed
Malter, MP, Helmstaedter, C, Urbach, H, et al. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010;67:470–478Google Scholar
Pradeep, K, Sinha, S, Mahadevan, A, et al. Clinical, electrophysiological, imaging, pathological and therapeutic observations among 18 patients with Rasmussen’s encephalitis. J Clin Neurosci 2016;25:96–104CrossRefGoogle ScholarPubMed
Marras, CE, Granata, T, Franzini, A, et al. Hemispherectomy and functional hemispherectomy: indications and outcome. Epilepsy Res 2010;89:104–112Google Scholar
Hanly, JG, Urowitz, MB, Su, L, et al. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum 2012;71:1502–1509CrossRefGoogle ScholarPubMed
Olmez, I, Moses, H, Sriram, S, et al. Diagnostic and therapeutic aspects of Hashimoto’s encephalopathy. J Neurol Sci 2013;331: 67–71CrossRefGoogle ScholarPubMed
Howell, KB, Katanyuwong, K, Mackay, MT, et al. Long-term follow-up of febrile infection-related epilepsy syndrome. Epilepsia 2012;53:101–110CrossRefGoogle ScholarPubMed
Gaspard, N, Foreman, BP, Alvarez, V, et al. Critical Care EEG Monitoring Research Consortium (CCEMRC). New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology 2015;85:1604–1613Google Scholar
Najjar, S, Pearlman, D, Zagzag, D, Devinsky, O. Spontaneously resolving seronegative autoimmune limbic encephalitis. Cogn Behav Neurol 2011;24:99–105Google Scholar
Beghi, E, Shorvon, S. Antiepileptic drugs and the immune system. Epilepsia 2011;52(Suppl 3):40–44Google Scholar
Dinarello, CA, Simon, A, van der Meer, JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11:633–652Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×